Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery

Launched by EUROPEAN INSTITUTE OF ONCOLOGY · Feb 20, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment option for patients with certain types of breast cancer, specifically those who have received chemotherapy before surgery and have shown no signs of cancer in their breast tissue after treatment. Instead of undergoing surgery, the study is testing whether a treatment using only radiation can be just as effective for those patients who have a complete response to the chemotherapy. To confirm this response, doctors will perform a special type of biopsy guided by ultrasound.

To be eligible for this trial, participants must be adults over 18 years old with a specific type of breast cancer that is either triple negative or HER2-positive, and their cancer should be in the early stages (T1-T2). They should have received at least 12 weeks of chemotherapy before joining the study. Participants can expect to receive radiation treatment instead of surgery and will be closely monitored to ensure their safety and the effectiveness of this approach. This trial is currently recruiting participants, and it aims to offer an alternative for patients who wish to avoid surgery while still receiving effective care for their breast cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age\> 18 years
• • infiltrating breast carcinoma, non-special histotype, triple negative or HER2 +, T1-T2 N0
• • single lesion
• • neo-adjuvant chemotherapy treatment for at least 12 weeks according to clinical practice
• • conservative surgery proposal
• • M0
• • tumour bed identified by breast markers placed in pre NACT by radiologist
• Exclusion Criteria:
• • Bilateral or multicentric tumour
• • Presence of microcalcifications visualised on mammography
• • Presence of associated DCIS
• • Positive history of previous breast cancer
• • Positive history of medical or psychiatric conditions preventing adherence to the protocol
• • High risk patient